SecBot SecBot
SECBOTREPLAY Home › Report › COLL

COLL · Collegium Pharmaceutical is acquiring AZSTARYS, a differentiated ADHD…

Collegium Pharmaceutical, Inc. · PRESS-RELEASE filed Mar 19, 2026 at 08:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 19, 2026 at 08:00 ET

Collegium Pharmaceutical is acquiring AZSTARYS, a differentiated ADHD treatment, from Corium Therapeutics for $650 million in cash plus up to $135 million in milestone payments. The deal expands Collegium’s ADHD portfolio, is expected to be immediately accretive to adjusted EBITDA, and will be funded with cash on hand and a $300 million delayed draw term loan. AZSTARYS is projected to generate over $50 million in pro forma net revenue in the second half of 2026.

  • Collegium is acquiring AZSTARYS for $650 million in cash, with potential milestone payments up to $135 million.
  • AZSTARYS is a CNS stimulant for ADHD with dual-release mechanism and expected patent protection into 2037.
  • The acquisition is expected to be immediately accretive to adjusted EBITDA and generate over $50 million in pro forma net revenue in second half 2026.
  • Deal to be funded with cash on hand and $300 million delayed draw term loan; net leverage expected at ~2x post-close.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access